Determining the Mechanisms of Loss of CAR T Cell Persistence

ConditionsAcute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia Not Having Achieved Remission Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, in Relapse

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeUp to 25

SponsorUniversity College, London

About this trial

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Eligibility criteria

Qualifiers

Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)

Written informed consent

Disqualifiers

Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial

Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

University College, London

Lead sponsor

Source ClinicalTrials.gov